Bone · VITD-BONE-03 · v2
Borderline: within 4 points of the Doubtful/Refuted boundary, so a re-grade could land either side.
Several large, well-run trials gave vitamin D to adults who were not short of it, or to unselected older adults, and found no gain in bone density [7][4][10][16][12]. At high daily doses, bone density actually fell rather than rose [1][11]. A real benefit showed up only in a narrow group: adults who started with very low vitamin D levels (25OHD at or below 30 nmol/L) [5][6]. Some studies that looked positive also gave calcium at the same time, so any bone change cannot be pinned on vitamin D alone [9][12][23]. Because the claim is written as a blanket statement about all adults, the panel found the best evidence points against it, with the exception confined to deficient people.
Large double-blind RCTs in replete or unselected adults show no between-group increase in BMD: VITAL (N=771) found no effect on spine, hip, whole body or structure [7], and Hansen [4], Aspray (N=379) [10], Lerchbaum [16] and Smith [12] concur. In vitamin-D-sufficient adults aged 55 to 70, daily 4000 IU and 10,000 IU produced significantly lower radial volumetric BMD than 400 IU, a negative dose-response [1], with greater loss in females [11]. A positive signal is restricted to baseline 25OHD at or below 30 nmol/L [5][6]. Records such as Rahme [9], Smith [12] and the uncontrolled single-arm Saha [23] co-administer calcium, confounding attribution to vitamin D. The contested point: The division is scope, not direction: the evidence supports a benefit only in adults deficient at baseline (25OHD ≤30 nmol/L) [5][6] while contradicting benefit in replete or unselected adults [7][1]. Whether the deficiency-subgroup signal is robust is itself qualified because [5] frames its threshold analysis as exploratory.
All 24 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Vitamin D, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The claim is unconditional ('in adults'), but the only clean positive BMD signal is confined to adults deficient at baseline (25OHD ≤30 nmol/L) [5][6]; the claim overreaches far beyond where the effect exists.
In vitamin-D-replete adults, high-dose supplementation significantly LOWERED volumetric BMD [1][11] — the evidence moves in the opposite direction to the claim, not merely null.
Where it remains uncertain. The one clean positive signal sits in a deficiency subgroup described as exploratory [5], while several nominally positive records are confounded by co-administered calcium [9][12][23].
Aleatory
The deficiency-threshold benefit in [5] rests on only n=46 with baseline 25OHD ≤30 nmol/L, so random variation around the estimate is large.
Epistemic
Most trials enrolled replete or insufficient (not severely deficient) adults; the corpus contains few participants at 25OHD ≤30 nmol/L to characterise the one subgroup where effect may exist [5][6].
Inferential
The corpus measures BMD, not fractures, so any inference to clinical bone benefit is indirect.
The load-bearing papers from a corpus of 24, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Null BMD effect in insufficient postmenopausal adults.
“we found that low- and high-dose cholecalciferol were equivalent to placebo in their effects on bone and muscle outcomes in this cohort of postmenopausal women with 25(OH)D levels less than 30 ng/mL.”
Panel auditInternal validity: high · scope of inference: Postmenopausal women ≤75 years with 25(OH)D 14-27 ng/mL and no osteoporosis.Key limitations: 1-year duration · single center · insufficiency range only
Null for untargeted adults; establishes that benefit is not general.
“With baseline 25-hydroxyvitamin D ≤ 30 nmol L-1 (n = 46), there were between-groups BMD changes at the spine and femoral sites of ~2%, significant in the spine and femoral neck”
Panel auditInternal validity: medium · scope of inference: Older community-resident adults; exploratory benefit in those with baseline 25(OH)D ≤30 nmol/L.Key limitations: substudy · conditional benefit only in deficient subgroup · exploratory analyses
Independently confirms the deficiency-conditional nature of any benefit.
“It is concluded that vitamin D supplements only increase bone density in adults with nadir 25OHD ≤30 nmol/L.”
Panel auditInternal validity: medium · scope of inference: Postmenopausal women; benefit only in those with nadir 25(OH)D ≤30 nmol/L.Key limitations: subgroup-conditional benefit · secondary analysis · 1-year duration
Shows high-dose vitamin D reduces, not increases, BMD in replete adults — contradicts claim direction.
“Among healthy adults, treatment with vitamin D for 3 years at a dose of 4000 IU per day or 10 000 IU per day, compared with 400 IU per day, resulted in statistically significant lower radial BMD”
Panel auditInternal validity: high · scope of inference: Healthy, vitamin D-sufficient community adults 55-70 with baseline 25(OH)D 30-125 nmol/L.Key limitations: no placebo arm, only dose comparison · vitamin D-sufficient at baseline · single center
4 of 24 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
The best-powered evidence contradicts an unconditional benefit, limiting any true effect to a deficient subgroup, which the claim as worded does not capture.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No confirmatory trial in baseline-deficient adults. The only clean positive signal is confined to 25OHD ≤30 nmol/L but rests on small exploratory subgroups [5][6], the exact population the blanket claim would most need to hold in. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A double-blind RCT enrolling only adults with baseline 25OHD ≤30 nmol/L, prespecifying BMD change as the primary endpoint, with vitamin D given without calcium.
Open question: Does vitamin D alone increase BMD in adults with baseline 25OHD ≤30 nmol/L when confirmed in an adequately powered, prespecified trial? Why it is still open: The signal in [5][6] is from small, exploratory or secondary threshold analyses, not a trial designed around the deficient subgroup.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 26 Oct 2026 · protocol v0.19